Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41

AIDS

Volumn 16, Issue 13, 2002, Pages 1731-1741

  Clerici, Mario ^a   Barassi, Claudia ^a   Devito, Claudia ^a   Pastori, Claudia ^a   Piconi, Stefania ^a   Trabattoni, Daria ^a   Longhi, Renato ^a   Hinkula, Jorma ^a   Broliden, Kristina ^a   Lopalco, Lucia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Antibodies; Exposed uninfected; gp41; HIV 1; IgA; Neutralization

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN A; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; EPITOPE MAPPING; FEMALE; GIANT CELLS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN A; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; VIRUS REPLICATION;

EID: 18644386762     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200209060-00004     Document Type: Article

References (45)

1. Rowland-Jones SL, McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr Opin Immunol 1995, 7:448-455.
2. Shearer G, Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today 1996, 17:21-24.
3. Burastero SE, Gaffi D, Lopalco L et al. Autoantibodies to CD4 in HIV type I-exposed seronegative individuals. AIDS Res Hum Retroviruses 1996, 12:273 -280.
4. Mazzoli S, Trabattoni D, Lo Caputo S et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997, 3:1250-1257.
5. Lehner T, Wang Y, Doyle C et al. Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques. Eur J Immunol 1999, 29:2427-2435.
6. Mazzoli S, Lopalco L, Salvi A et al. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 1999, 180:871-875.
7. Lopalco L, Pastori C, Cosma A et al. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retroviruses 2000, 16:109-115.
8. Lopalco L, Barassi C, Pastori C et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol 2000, 164:3426-3433.
9. Paxton WA, Martin SR, Tse D et al. Relative resistance to HIV1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nat Med 1996, 2:412-417.
10. Liu R, Paxton W, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996, 86:1-11.
11. Samson M, Libert F, Doranz B et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemochine receptor gene. Nature 1996, 382:722-725.
12. Ranki AM, Mattinen K, Yarchoan R et al. T cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS 1989, 3:63-69.
13. Clerici M, Giorgi JV, Chou CC et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type-1 in seronegative homosexual men with recent sexual exposure to HIV 1. J Infect Dis 1992, 165:1012-1019.
14. Clerici M, Sison AV, Berzofsky JA et al. Cellular immune factors associated with mother-to-infant transmission of HIV. AIDS 1993, 7:1427-1433.
15. Clerici M, Levin JM, Kessler HA et al. HIV specific T helper activity in seronegative health care workers exposed to contaminated blood. JAMA 1994, 271:42-46.
16. Furci L, Scarlatti G, Burastero S et al. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 1997, 186:455-460.
17. Rowland-Jones S. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995, 1:59-64.
18. De Maria A, Cirillo C, Moretta L. Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers. J Infect Dis 1994, 170:1296-1299.
19. Kaul R, Trabattoni D, Bwayo JJ et al. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 1999, 14:23-29.
20. Devito C, Hincula J, Kaul R et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralises primary HIV-1 isolates. AIDS 2000, 14:1917-1920.
21. Beyrer C, Artenstein AW, Rugpao S et al. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female. J Infect Dis 1999, 179:59-67.
22. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression by a deletion allele of the CKR5 structural gene. Science 1996, 273:1856-1861.
23. Quillent C, Oberlin E, Braun J et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998, 351:14-18.
24. Moore JP, McKeating JA, Huang Y, Ashkenazi A, Ho DD. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycopreotein gp120 retention from sCD4-sensitive isolates. J Virol 1992, 66:235-243.
25. Pesenti E, Pastore C, Lillo F, Siccardi AG, Vercelli D, Lopalco L. Role of CD4 and CCR5 levels in the susceptibility of primary macrophages to infection by CCR5-dependent HIV type 1 isolates. AIDS Res Hum Retroviruses 1999, 15: 983-987.
26. Zolla Pazner S. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res Hum Retroviruses 1995, 11:1449-1458.
27. Lopalco L, Longhi R, Ciccomascolo F et al. Identification of human immunodeficiency virus type 1 glicoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies. AIDS Res Hum Retroviruses 1993, 9:33-39.
28. Muster T, Guinea R, Trkola A et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994, 68: 4031-4034.
29. Skott P, Lucht E, Julander I, Dillner J, Bjorling E. Salivary sIgA response in HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 21:73-80.
30. Kozlowski PA, Jackson S. Serum IgA subclasses and molecular forms in HIV infection: selective increases in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins. AIDS Res Hum Retroviruses 1992, 8:1773-1780.
31. Robert-Guroff M, Goedert JJ, Naugle CJ, Jennings AM, Blattner WA, Gallo RC. Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6 year prospective study. AIDS Res Hum Retroviruses 1988, 4:343-350.
32. Shafferman A, Lennox J, Grosfeld H, Sadoff J, Redfield RR, Burke DS. Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stages of HIV infection. AIDS Res Hum Retroviruses 1989, 5:33-39.
33. Ugen KE, Goedert JJ, Boyer J et al. Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest 1992, 89:1923-1930.
34. Burnett PR, VanCott TC, Polonis VR, Redfield RR, Birx DL. Serum IgA-mediated neutralization of HIV type 1. J Immunol 1994, 152:4642-4648.
35. Vanini S, Longhi R, Lazzarin A, Vigo E, Siccardi AG, Viale G. Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies. AIDS 1993, 7:167-174.
36. Schulz T, Jameson BA, Lopalco L, Siccardi AG, Weiss R, Moore JP. Conserved Structural features in the interaction between retroviral surface and transmembrane glycoprotein? AIDS Res Hum Retroviruses 1992, 8:1571-1580.
37. Helseth E, Olshevsky U, Furman C, Sodroski J. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 1991, 65:2119- 2123.
38. Freed EO, Martin MA. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 1995, 270:23883-23886.
39. Luciw PA. Human Immunodeficiency viruses and their replication. In: Fields in Virology. Edited by Fields BN, Knipe DM, Howley PM et al. Lippincott-Raven, 1996:1891-1952.
40. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998, 93:681-684.
41. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 1999, 283:357-362.
42. Baba TW, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immundeficiency virus infection. Nat Med 2000, 6:200-206.
43. Mascola JR, Frankel SS, K. B. HIV-1 entry at the mucosal surface: role of antibodies in protection. AIDS 2000, 14: S167-S174.
44. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999, 99:103-115.
45. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998, 95:15613-15617.